Our Current Trials

Condition	Trial Name	Sponsor
Solid Tumors	1719-001: MRTX1719 in MTAP Deleted Advanced Solid Tumors	Mirati Therapeutics, Inc.
Breast Cancer	ACE-Breast-03: ARX788 in HER2-positive, Metastatic Breast Cancer Subjects Previously Treated with T-DXd	Ambrx, Inc.
Non-Small Cell Lung Cancer	ARTEMIA: Trial of Therapeutic Cancer Vaccine OSE2101 in Patients With Non-Small Cell Lung Cancer and Secondary Resistance to Immune Checkpoint Inhibitor	OSE Immunotherapeutics
Breast Cancer	ASCENT-05: Adjuvant Sacituzumab Govitecan Plus Pembrolizumab for Patients with Triple Negative Breast Cancer	Gilead Sciences, Inc.
Cachexia	AV-380-22-102: A Dose Escalation Study of GDF-15 Inhibitor AV-380 in Metastatic Cancer Patients with Cachexia	AVEO Pharmaceuticals, Inc.
Colon Cancer	AZUR-2: Perioperative Dostarlimab in Patients with dMMR/MSI-H Resectable Colon Cancer	GlaxoSmithKline
Non-Small Cell Lung Cancer	AndroMETa-Lung-536: Telisotuzumab Adizutecan in Combination With IV Budigalimab in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC	AbbVie
Chronic Lymphocytic Leukemia	BGB-11417-204: Sonrotoclax Combined With Zanubrutinib Versus Zanubrutinib Alone in Participants With Previously Untreated Chronic Lymphocytic Leukemia	BeOne Medicines
Breast Cancer	BRIA-ABC: Bria-IMT plus Immunotherapy for Patients with Pre-Treated Metastatic Breast Cancer	BriaCell Therapeutics Corporation
Non-Small Cell Lung Cancer	CYBRID-01: Observational lung trial to collect tissue to train and validate a live tumor diagnostic platform	Elephas Biosciences Corporation
Breast Cancer	DB-1303-O-1001: A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors	DualityBio Inc.
Prostate Cancer	Debio 4228-201: Study of Extended Release GnRH in Newly Diagnosed Locally Advanced or Metastatic Prostate Cancer	Debiopharm International SA
Breast Cancer	ELEVATE: Elacestrant Combinations for the Treatment of ER+ HER2- Metastatic Breast Cancer After CDK4/6 Inhibitor	Stemline Therapeutics, Inc.
Breast Cancer	EvoPAR-Breast01: Saruparib (AZD5305) Plus Camizestrant Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative, BRCA1, BRCA2, or PALB2m Advanced Breast Cancer	AstraZeneca
Prostate Cancer	EvoPAR-Prostate01: Saruparib (AZD5305) vs Placebo in Men With Metastatic Castration-Sensitive Prostate Cancer Receiving Physician's Choice New Hormonal Agents	AstraZeneca
Central Nervous System Cancer	F8294-201b: BRAF Inhibitor FORE8394 in Recurrent/Refractory BRAF V600E Mutant CNS Malignancy	Fore Biotherapeutics
Breast Cancer	First-in-Human, Escalating Oral Dose Study of RGT-419B Given Alone and with Endocrine Therapy in Subjects with Hormone Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative Advanced/Metastatic Breast Cancer	Regor Pharmaceuticals Inc.
Gastric or Gastroesophageal Junction Cancer	GEMINI-C: First Line Treatment for Patients with an Advanced/Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma	AstraZeneca
Colorectal Cancer	INTRINSIC: A Multi-Arm Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer	Hoffmann-La Roche
Non-Small Cell Lung Cancer	KRAScendo-1: A Study Evaluating the Efficacy and Safety of Divarasib Versus Sotorasib or Adagrasib in Participants With Previously Treated KRAS G12C-positive Advanced or Metastatic Non-Small Cell Lung Cancer	Hoffmann-La Roche
Non-Small Cell Lung Cancer	KRYSTAL-17: Adagrasib Combinations in Patients with KRAS G12C Mutation	Mirati Therapeutics, Inc.
Non-Small Cell Lung Cancer	LUNAR-2: TTFields With Pembrolizumab + Platinum-based Chemotherapy for Metastatic NSCLC	NovoCure GmbH
Multiple Myeloma	M22-574: Study of Treatment with Bispecific Antibody ABBV-383 in Relapsed/Refractory Multiple Myeloma After at Least 2 Prior Lines of Therapy	AbbVie
Follicular Lymphoma or Marginal Zone Lymphoma	MAHOGANY: A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refractory Follicular or Marginal Zone Lymphoma	BeOne Medicines
Non-Small Cell Lung Cancer	MARIGOLD: A Study to Compare ABP 234 and Keytruda® (Pembrolizumab) in Participants With Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer	Amgen
Colorectal Cancer	MBI-006-COMUNITY: Combined AlloStim+Anti-PD-L1 in MSS Metastatic Colorectal Cancer	Mirror Biologics, Inc.
Hyperkalemia/Chronic Kidney Disease	NYH-01: Hyperkalemia/Chronic Kidney Disease	Relypsa
Advanced Solid tumors	Phase 1 Study of SGN-B6A in Advanced Solid Tumors	Seagen Inc.
Non-Small Cell Lung Cancer	Phase 2/3 Study of Fianlimab (Anti-LAG-3 Antibody) in Combination With Cemiplimab (Anti-PD-1 Antibody) Versus Cemiplimab Monotherapy in First-Line Treatment of Patients With Advanced Non-Small Cell Lung Cancer	Regeneron Pharmaceuticals
Multiple Myeloma	Prospective Observational Study to Evaluate an Electronic Health Record-Based Data Collection Infrastructure for Capturing the Risk Factors for Severe and Fatal Infusion related Reactions in Newly Diagnosed Multiple Myeloma Participants Treated with Daratumumab (Intravenous or Subcutaneous)	J&J
Solid Tumors or Multiple Myeloma	QXL138AM-001: Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma	Nammi Therapeutics Inc
ITP, wAIHA, CAD	RUBY-4: Povetacicept (ALPN-303) for Patients with Autoimmune Cytopenias	Alpine Immune Sciences, Inc.
Diffuse Large B-Cell Lymphoma	SKYGLO: Glofitamab in Combination With Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (Pola-R-CHP) Versus Pola-R-CHP in Previously Untreated Patients with Large B-Cell Lymphoma	Hoffmann-La Roche
Head and Neck Squamous Cell Carcinoma	STELLAR-305: Zanzalintinib in Combination with Pembrolizumab as First Line Therapy for Recurrent or Metastatic Disease	Exelixis
Multiple Myeloma	SUCCESSOR-1: A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)	Celgene Corporation
	TEMPLATE
Non-Small Cell Lung Cancer	TRITON: First-Line Treatment in Metastatic Non-Small Cell Lung Cancer Patients with Non-Squamous Histology	AstraZeneca LP
Non-Small Cell Lung Cancer	TeLuRide-005: EIK1001 in Combination With Pembrolizumab and Chemotherapy in Patients With Stage 4 Non-Small Cell Lung Cancer	Eikon Therapeutics
Cancer Diagnosis	[Registry] MSK-IMPACT/ACCESS Genomic Profiling in Cancer Patients	Memorial Sloan Kettering Cancer Center
Various Indications	[Sample Collection] Clinical Biospecimen Procurement Protocol to Support Advancements in Medical Diagnoses of Diseases (PROMEDx)	Precision for Medicine
Solid Tumors	[Sample Collection] Collection and Distribution of Biofluids for Research Purposes	Bluestar Genomics
Solid Tumors	[Sample Collection] Detecting cancers Earlier Through Elective plasma-based Cancer SEEK Testing (DETECT-ASCEND 2)	Exact Sciences Thrive LLC
Various Indications	[Sample Collection] Prospective Collection of Samples for Research (SERATRIALS-05035)	SERATRIALS, LLC.
Solid Tumors	[Sample Collection] Vallania: A Case Control Study for the Development of Multiomics Blood Tests for Cancer Screening	Freenome Holdings Inc.

Our Current Trials

Call Us